[ad_1]
The Central Department of Pharmaceutical Affairs disclosed the reason for the acquisition of the preparations "Avistin" (B7254B01) and the preparation of Brigitta 240 mg, Operations No. H022B03, and H0304B04, confirming that these operations had been cheated according to the manufacturer.
The Central Administration of Pharmaceutical Affairs (CMA) has listed the products used to treat bad cancer. It has issued Circular No. 28 of 2019 to obtain the products of the market.
The ministry has sent the pamphlet to all health directorates in the country to take the necessary measures, as well as to the company producing these products and the distribution companies to freeze the balance of these operations, explaining the measures in this respect to the central administration.
This article is adapted from the original news source:
Crescent today
[ad_2]
Source link
